H. Lee Moffitt Cancer Center & Research Institute

Cancer Control Journal Vol 4, No 5
CME Pretest

In this issue, the topic of leukemia is addressed. First, answer the pretest questions below. After reading the articles, proceed with answering the CME posttest questions.


This Journal provides 4 hours of Category I Continuing Medical Education

Complimentary CME Credits

Physicians can earn up to 4 credit hours of Category I for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions on the posttest at the end of this issue. Complete instructions are given on the posttest pages. Every successfully answered 10 questions will earn 1 credit hour. CME is presented by an unrestricted educational grant from Bristol-Myers Oncology Division.

Educational Objectives

After reading this issue, clinicians will be expected to:

  • be aware of the current molecular and cytogenetic testing techniques used in hematologic malignancies;
  • be familiar with identification, evaluation, and therapeutic options for adults with acute myelogenous leukemia;
  • recognize the effectiveness of support groups in helping patients to cope with the emotional and practical impact of cancer;
  • understand the design, analysis, and evaluation of clinical investigations; and
  • be aware of the increased potential for polypharmacy and drug interactions in older patients with cancer.

This program was planned in accordance with ACCME Essentials.
Release Date: September 1, 1997 Expiration Date: September 1 , 1998


Pretest


1. The myelodysplastic syndrome or acute myelogenous leukemia that is related to prior alkylating agent therapy often exhibits abnormalities involving which chromosomes?
a. 11 and 21
b. 9 and 22
c. 4 and 1
d. 5 and 7
2. Which translocation produces the "Philadelphia chromosome" in chronic granulocytic leukemia?
a. t(11;14)
b. 11q23
c. t(9;22)
d. 21q22
3. Repeated or interim statistical analyses:
a. improve the statistical robustness of the final outcome measurements
b. minimize the risk of previously unforseen hazardous events occurring
c. provide an accurate prediction about what the final results of the study will demonstrate
d. increase the chance of observing a statistically significant difference due to chance



© Copyright 1996 - 2009 H. Lee Moffitt Cancer Center & Research Institute